Venus Concept (NASDAQ: VERO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.090 | -0.130 | -0.0400 | ||||
REV | 27.020M | 26.406M | -614.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Venus Concept (NASDAQ: VERO) through any online brokerage.
Other companies in Venus Concept’s space includes: Sonendo (NYSE:SONX), Bluejay Diagnostics (NASDAQ:BJDX), Talis Biomedical (NASDAQ:TLIS), Tivic Health Systems (NASDAQ:TIVC) and NeuroOne Medical Tech (NASDAQ:NMTC).
The latest price target for Venus Concept (NASDAQ: VERO) was reported by BTIG on Friday, June 24, 2022. The analyst firm set a price target for 5.50 expecting VERO to rise to within 12 months (a possible 1022.45% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Venus Concept (NASDAQ: VERO) is $0.49 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Venus Concept.
Venus Concept’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for Venus Concept.
Venus Concept is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.